Ticagen 90mg (Ticagrelor)

Adult dose

This drug should not be used concomitantly with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment is recommended for 12 months unless discontinuation of this drug is clinically necessary. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. In patients with acute coronary syndrome who have an increased risk of bleeding and have undergone percutaneous coronary intervention (PCI), monotherapy with this drug (discontinuing aspirin) may be considered after 3 months of concomitant treatment with this drug and aspirin. (See 3. Patients Requiring Caution.) Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients who were taking 90mg of this drug or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this drug. Treatment with this drug may also be initiated in patients within 2 years after myocardial infarction or within 1 year after discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). The safety and efficacy of this drug were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. For patients with acute coronary syndrome, refer to the relevant dosage and administration instructions. Data on the safety and efficacy of this drug when used for more than 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this drug should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended in patients with acute ischemic stroke or high-risk transient ischemic attack. This drug is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this drug into a fine powder, disperse it in half a glass of water, and drink the mixture immediately. Rinse the cup used with half a glass of water and drink it again. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the nasogastric tube with water after administration. When switching from another antiplatelet drug to this drug, start this drug 24 hours after the last dose of the previous medication. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dosage adjustment is necessary in patients with renal impairment. No dosage adjustment is necessary in patients with mild hepatic impairment. This drug has not been studied in patients with severe hepatic impairment, and experience with its use in patients with moderate hepatic impairment is limited.

Child dose

Safety and efficacy have not been established in pediatric patients under 18 years of age (see “Other”).

This medication prevents blood clotting to prevent thrombosis. However, it may cause bleeding, so it should not be used in patients with existing bleeding or a history of intracranial hemorrhage. If surgery is planned, it should be discontinued at least 5 days prior to the procedure to reduce the risk of bleeding. If blood pressure drops or bleeding symptoms occur, inform healthcare personnel immediately and proceed with bleeding treatment without stopping the medication if possible. Patients with allergies to any component of this medication, those with pathological bleeding, patients with severe liver dysfunction, and those taking strong CYP3A4 inhibitors should not take this medication. Patients at high risk of bleeding or those taking other medications that increase bleeding risk should use this medication cautiously and be aware of bleeding symptoms. Patients scheduled for surgery must inform healthcare providers about this medication's use and modulate when to discontinue it if necessary. Patients at risk of bradycardia (slow heart rate) or heart rhythm issues should consult with healthcare personnel before taking this medication. Asthma or chronic obstructive pulmonary disease patients should be particularly cautious as shortness of breath may occur. Women who are pregnant or breastfeeding should consult with a physician before using this medication, and effective contraception should be utilized if pregnancy is desired. Children under 18 years of age are not recommended to use this medication as its safety and efficacy have not been established. In cases of overdose, the risk of bleeding increases, so immediate hospital visit for appropriate treatment is necessary. This medication has many drug interactions, so it is essential to inform healthcare personnel about all medications currently taken. Caution is advised when driving or operating machinery due to potential dizziness or confusion. The most common side effects of this medication are bleeding and respiratory difficulty, and it is essential to inform healthcare personnel immediately if any abnormal symptoms arise.

Hemorrhage, dyspnea, hyperuricemia, gout, confusion, dizziness, fainting, headache, intracranial hemorrhage, ocular hemorrhage, vertigo, ear hemorrhage, hypotension, respiratory tract hemorrhage, gastrointestinal hemorrhage, diarrhea, nausea, indigestion, constipation, retroperitoneal hemorrhage, subcutaneous or skin hemorrhage, rash, itching, muscle hemorrhage, urinary tract hemorrhage, genital hemorrhage, increased serum creatinine, post-procedural hemorrhage, traumatic hemorrhage, thrombotic thrombocytopenic purpura, bradyarrhythmia, atrioventricular block, angioedema, Cheyne-Stokes respiration, central sleep apnea, chest pain, cough, pulmonary hemorrhage, pharyngitis, upper respiratory infection, asthma, pleural effusion, bronchitis, pneumothorax, pneumonia, pulmonary edema, weakness, anaphylactic shock, epistaxis, hemoptysis, hematoma, cerebral hemorrhage, spinal canal stenosis, dementia, migraine, paralysis, gait abnormalities, rectal bleeding, anal bleeding, appendicitis, tendon disorder, bursitis, rhabdomyolysis, hepatitis, snoring, aneurysm, heart failure, palpitations, ventricular tachycardia, arrhythmia, ventricular fibrillation, cardiac arrest, ventricular fibrillation, urinary tract infection, kidney stones, cerebral ischemia, venous stenosis, cerebral infarction, arterial stenosis, angina pectoris, coronary thrombosis, myocardial ischemia, anemia, vestibular disorders, malignant neoplasm of male genital organs, chemical toxicity, post-procedural hematoma, laceration, road traffic accident, trauma, sinusitis, chronic obstructive pulmonary disease, laryngitis, increased sputum, bronchiectasis, sleep apnea, pulmonary congestion, oral edema, influenza-like illness, tuberculosis infection, hyperthermia, unspecified hernia, shortness of breath, generalized edema, thrombosis, leg venous thrombosis, deep venous thrombosis, cardiac thrombus, coagulation disorders, thrombocythemia, speech disorders, cerebral hypoxia, scalp tenderness, peripheral neuropathy, neck stiffness, voice disorders, seizures, neuropathy, neuralgia, movement disorders, tremors, lower limb paralysis, coma, sensory loss, oral pain, gastroenteritis, belching, irritable bowel syndrome, stomatitis, ulcerative stomatitis, benign gastrointestinal neoplasm, dental diseases, tongue diseases, dry mouth, gastritis, gastric ulcer, abdominal distension, gingivitis, cavities, tendinitis, osteoarthritis, chondrocalcinosis, spinal osteoarthritis, back pain, myalgia, skeletal pain, arthralgia, muscle tension disorders, fractures, arthritis, muscle weakness, contact dermatitis, fungal dermatitis, skin diseases, erythematous rash, keratosis, acute urticaria, onychomycosis, hair loss, scleroderma, dermatofibroma, increased sweating, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, lipodystrophy, dehydration, thirst, hepatitis, cholelithiasis, gallbladder disease, increased alkaline phosphatase, fatty liver, drowsiness, neurosis, depression, hallucinations, memory abnormalities, erectile dysfunction, anxiety, orthostatic hypotension, exacerbation of hypertension, cyanosis, atrial fibrillation, frequency of urination, difficulty urinating, urinary retention, ocular hyperemia, ocular pain, visual disturbance, myocardial infarction, decreased blood iron, tinnitus, ear pain, lymphadenopathy, eosinophilia, leukocytosis, sexual dysfunction, benign prostatic hyperplasia, ovarian cysts, amenorrhea, vaginitis, loss of taste, olfactory distortion, increased TSH, hypothyroidism, injection site reactions, injection site pain, chemical toxicity, concussion, intervertebral disc disease, non-drug allergy, deviation of the nasal septum, surgical site reactions

This medication should be stored in a tight container, protected from air and moisture, at temperatures between 1 to 30 degrees Celsius. Proper storage helps maintain the efficacy and safety of the medication.

Appearance

Yellow, biconvex round film-coated tablets

Package unit

30 tablets (10 tablets/PTP x 3)